Venture capital investment in urology, 2011 to mid-2021


EDITORIAL COMMENT

Re: Venture capital investment in urology, 2011 to mid-2021

Briggs and colleagues have provided an overview of venture capital investment in Urology. They note that urologic venture capital funding has been allocated more toward surgical and therapeutic devices than pharmaceuticals or health care technology. While the authors have performed a comprehensive review of these commercial urology investments, there has also been significant venture capital, also known as private equity, investment in large urology groups in the United States. An excellent review of the evolving venture capital investment movement in physician’s urology group practices has been written by Kirsch and Kapoor. Unlike the investments in urology biotechnology, devices and health systems that have remained stable over ten years as demonstrated by Briggs and associates, private equity acquisitions have accelerated to become a dominant form of urology practice consolidation in recent years. These ventures involving equity investment in urology practices have achieved significant market influence in certain regions. In the future, more research is needed to assess the impact of private equity investment in all areas of urology research, product development and patient care.

Leonard G. Gomella, MD, FACS
Department of Urology
Thomas Jefferson University and Hospital
Philadelphia, PA, USA

References